“I think given the general sense, we thought that we would be launching, at least within the U.S., in the earlier part of 2024.”

In context

“n the STELLAR trial, I think the label in the U.S. will be reasonably clear and follow that of what the STELLAR trial is. I think one of the things that was really important is that when we declared it, we didn't just declare a 6-minute walk. We declared a time to clinical worsening and death, which was really important because I think that creates a different scenario for us than what we had predicted previously in our ability to go-to-market outside of the U.S. So I think that will be in the label within the FDA. But I think where it's important is it may change the speed with which the international markets adopt sotatercept. I hope that gives you that general sense. But as we move this forward, we are looking, and I think we've said previously that we would have the file complete. And I think given the general sense, we thought that we would be launching, at least within the U.S., in the earlier part of 2024. Robert Davis: Yeah. Chris, this is Rob. So on the question of our infrastructure support and launch, we're actually well positioned. I would remind you that we currently market Adempas outside the United States, that is NPAH. So outside the U.S., we're going to be able to leverage our relationships and our infrastructure there. We -- obviously, we'll add to it. And then in the United States, this is in its first indications. Anyway, more of a rare disease. You're looking at about 150 specialty centers in the United States have actually prescribed this. So this -- we're not talking a large commercial footprint. This is more of a rare disease type of launch. And we've been focused on building out capabilities, particularly as we think about medical affairs, science liaisons and how do we ma”